Mechanisms of metabolic dysfunction in cancer-associated cachexia

Genes and Development

Volumn 30, Issue 5, 2016, Pages 489-501

  Petruzzelli, Michele ^a   Wagner, Erwin F ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Cancer associated cachexia (CAC); Metabolic failure; Skeletal muscle atrophy; White adipose tissue (WAT) browning

Indexed keywords

LIPID;

ADVANCED CANCER; BROWN ADIPOSE TISSUE; CACHEXIA; CANCER MORTALITY; CARBOHYDRATE METABOLISM; ENERGY BALANCE; FOOD INTAKE; GENERAL CONDITION DETERIORATION; HUMAN; INFLAMMATION; METABOLIC DISORDER; MORBIDITY; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; WHITE ADIPOSE TISSUE; COMPLICATION; ENDOCRINE SYSTEM; LIPID METABOLISM; LIVER; MUSCULAR ATROPHY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE, WHITE; CACHEXIA; CARBOHYDRATE METABOLISM; ENDOCRINE SYSTEM; HUMANS; INFLAMMATION; LIPID METABOLISM; LIVER; MUSCULAR ATROPHY; NEOPLASMS;

EID: 84959459753     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.276733.115     Document Type: Review

References (149)

1. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. 2004. Cancer cachexia is regulated by selectivetargeting of skeletal muscle gene products. J Clin Invest114: 370-378.
2. Agustsson T, D'Souza MA, Nowak G, Isaksson B. 2011. Mechanismsfor skeletal muscle insulin resistance in patients withpancreatic ductal adenocarcinoma. Nutrition 27: 796-801.
3. Anker SD, Coats AJ. 1999. Cardiac cachexia: a syndrome with impairedsurvival and immune and neuroendocrine activation.Chest 115: 836-847.
4. Argiles JM, Lopez-Soriano FJ. 1999. The role of cytokines in cancercachexia. Med Res Rev 19: 223-248.
5. Arruda AP, Milanski M, Romanatto T, Solon C, Coope A, AlbericiLC, Festuccia WT, Hirabara SM, Ropelle E, Curi R, et al.2010. Hypothalamic actions of tumor necrosis factor α providethe thermogenic core for the wastage syndrome in cachexia.Endocrinology 151: 683-694.
6. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W. 1987. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2: 1229-1232.
7. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. 1983.Stimulation of muscle protein degradation and prostaglandinE2 release by leukocytic pyrogen (interleukin-1). A mechanismfor the increased degradation of muscle proteins duringfever. N Engl J Med 308: 553-558.
8. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. 1995. Activationof the ATP-ubiquitin-proteasome pathway in skeletal muscleof cachectic rats bearing a hepatoma. Am J Physiol 268:E996-E1006.
9. Bauwens M, Wierts R, van Royen B, Bucerius J, BackesW, Mottaghy F, Brans B. 2014. Molecular imaging of brown adipose tissuein health and disease. Eur J Nucl Med Mol Imaging 41:776-791.
10. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. 2011. Ahumanized anti-IL-6 antibody (ALD518) in non-small celllung cancer. Expert Opin Biol Ther 11: 1663-1668.
11. Begg RW, Dickinson TE. 1951. Systemic effects of tumors inforce-fed rats. Cancer Res 11: 409-412.
12. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. 2010. Acute inhibition of myostatin-family proteinspreserves skeletal muscle in mouse models of cancer cachexia.Biochem Biophys Res Commun 391: 1548-1554.
13. Berriel Diaz M, Krones-Herzig A, Metzger D, Ziegler A, Vegiopoulos A, Klingenspor M, Muller-Decker K, Herzig S. 2008.Nuclear receptor cofactor receptor interacting protein 140controls hepatic triglyceride metabolism during wasting inmice. Hepatology 48: 782-791.
14. Beutler B, Cerami A. 1986. Cachectin and tumour necrosis factoras two sides of the same biological coin. Nature 320: 584-588.
15. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. 1985. Purificationof cachectin, a lipoprotein lipase-suppressing hormonesecreted by endotoxin-induced RAW 264.7 cells. J ExpMed 161: 984-995.
16. Bishop JS, Marks PA. 1959. Studies on carbohydrate metabolismin patients with neoplastic disease. II. Response to insulin administration.J Clin Invest 38: 668-672.
17. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, PoueymirouWT, Panaro FJ, Na E, Dharmarajan K, et al. 2001.Identification of ubiquitin ligases required for skeletal muscleatrophy. Science 294: 1704-1708.
18. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA. 2012. JAK/STAT3 pathway inhibitionblocks skeletal muscle wasting downstream of IL-6 and in experimentalcancer cachexia. Am J Physiol Endocrinol Metab303: E410-E421.
19. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, Rossi Fanelli F, Doglietto GB, Baccino FM. 2003. Increasedmuscle proteasome activity correlates with disease severity ingastric cancer patients. Ann Surg 237: 384-389.
20. Bruera E, Sweeney C. 2002. Palliative care models: internationalperspective. J Palliat Med 5: 319-327.
21. Cahlin C, Korner A, Axelsson H,WangW, Lundholm K, Svanberg E. 2000. Experimental cancer cachexia: the role of host-derivedcytokines interleukin (IL)-6, IL-12, interferon-γ, and tumornecrosis factor α evaluated in gene knockout, tumorbearingmice on C57 Bl background and eicosanoid-dependentcachexia. Cancer Res 60: 5488-5493.
22. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, et al. 2004.IKKβ/NF-κB activation causes severe muscle wasting inmice. Cell 119: 285-298.
23. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC. 1989. Interleukin-6 is the majorregulator of acute phase protein synthesis in adult humanhepatocytes. FEBS Lett 242: 237-239.
24. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B. 1985.Weightloss associated with an endotoxin-induced mediator fromperitoneal macrophages: the role of cachectin (tumor necrosisfactor). Immunol Lett 11: 173-177.
25. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH.2005. Role of leptin and melanocortin signaling in uremia-associatedcachexia. J Clin Invest 115: 1659-1665.
26. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL. 2009. During muscle atrophy, thick,but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 185: 1083-1095.
27. Cohen S, Nathan JA, Goldberg AL. 2015. Muscle wasting in disease:molecular mechanisms and promising therapies. NatRev Drug Discov 14: 58-74.
28. Corcoran MP, Lamon-Fava S, Fielding RA. 2007. Skeletal musclelipid deposition and insulin resistance: effect of dietary fattyacids and exercise. Am J Clin Nutr 85: 662-677.
29. Cori CF, Cori GT. 1925. The carbohydrate metabolism of tumors:II. Changes in the sugar, lactic acid, and CO2-combining powerof blood passing through a tumor. J Biol Chem 65: 397-405.
30. Costa G. 1977. Cachexia, the metabolic component of neoplasticdiseases. Cancer Res 37: 2327-2335.
31. Costa G, Holland JF. 1962. Effects of Krebs-2 carcinoma on thelipide metabolism of male Swiss mice. Cancer Res 22:1081-1083.
32. Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, Baccino FM. 1993. Tumor necrosis factor-α mediateschanges in tissue protein turnover in a rat cancer cachexiamodel. J Clin Invest 92: 2783-2789.
33. Cousin B, Cinti S, Morroni M, Raimbault S, Ricquier D, Penicaud L, Casteilla L. 1992. Occurrence of brown adipocytes in ratwhite adipose tissue: molecular and morphological characterization.J Cell Sci 103: 931-942.
34. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, et al. 2009. Identificationand importance of brown adipose tissue in adult humans.N Engl J Med 360: 1509-1517.
35. Dahlman I, Mejhert N, Linder K, Agustsson T, Mutch DM,Kulyte A, Isaksson B, Permert J, Petrovic N, Nedergaard J, et al. 2010. Adipose tissue pathways involved in weight lossof cancer cachexia. Br J Cancer 102: 1541-1548.
36. Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, et al. 2011.Adipose triglyceride lipase contributes to cancer-associatedcachexia. Science 333: 233-238.
37. DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, Taylor JE, Halem HA, Dong JZ, Datta R, et al. 2007. Ghrelintreatment causes increased food intake and retention of leanbody mass in a rat model of cancer cachexia. Endocrinology148: 3004-3012.
38. De Larichaudy J, Zufferli A, Serra F, Isidori AM, Naro F, Dessalle K, Desgeorges M, Piraud M, Cheillan D, Vidal H, et al. 2012.TNF-α-and tumor-induced skeletal muscle atrophy involvessphingolipid metabolism. Skelet Muscle 2: 2.
39. Deutz NE, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, van Helvoort A,Wolfe RR. 2011. Muscle protein synthesisin cancer patients can be stimulated with a specially formulatedmedical food. Clin Nutr 30: 759-768.
40. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. 2013. Effects of enobosarm onmusclewasting and physical function in patients with cancer:a double-blind, randomised controlled phase 2 trial. LancetOncol 14: 335-345.
41. Donovan H. 1954. Malignant cachexia. ProcR Soc Med 47: 27-31.
42. Dumas JF, Goupille C, Julienne CM, Pinault M, Chevalier S, Bougnoux P, Servais S, Couet C. 2010. Efficiency of oxidativephosphorylation in liver mitochondria is decreased in a ratmodel of peritoneal carcinosis. J Hepatol 54: 320-327.
43. Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S.2014. Highlights from the 7th cachexia conference: musclewasting pathophysiological detection and novel treatmentstrategies. J Cachexia Sarcopenia Muscle 5: 27-34.
44. Editors. 1929. Cachexia in cancer. N Engl J Med 201: 956-957.
45. E.F.B. 1909. The natural history of cancer, with special referenceto its causation and prevention lectures on the pathology ofcancer. Nature 79: 391-392.
46. Egerman MA, Glass DJ. 2014. Signaling pathways controllingskeletal muscle mass. Crit Rev Biochem Mol Biol 49: 59-68.
47. Evans WK, Makuch R, Clamon GH, Feld R,Weiner RS, Moran E, Blum R, Shepherd FA, Jeejeebhoy KN, DeWys WD. 1985. Limitedimpact of total parenteral nutrition on nutritional statusduring treatment for small cell lung cancer. Cancer Res 45:3347-3353.
48. FanW, Boston BA, Kesterson RA, Hruby VJ, Cone RD. 1997. Roleof melanocortinergic neurons in feeding and the agouti obesitysyndrome. Nature 385: 165-168.
49. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. 2011.Definition and classification of cancer cachexia: an internationalconsensus. Lancet Oncol 12: 489-495.
50. Fearon KC, Glass DJ, Guttridge DC. 2012. Cancer cachexia: mediators,signaling, and metabolic pathways. Cell Metab 16:153-166.
51. Fearon K, Arends J, Baracos V. 2013. Understanding the mechanismsand treatment options in cancer cachexia. Nat RevClin Oncol 10: 90-99.
52. Feldmann HM, Golozoubova V, Cannon B, Nedergaard J. 2009.UCP1 ablation induces obesity and abolishes diet-inducedthermogenesis in mice exempt from thermal stress by livingat thermoneutrality. Cell Metab 9: 203-209.
53. Figueroa-Clarevega A, Bilder D. 2015. Malignant Drosophila tumorsinterrupt insulin signaling to induce cachexia-like wasting.Dev Cell 33: 47-55.
54. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, Cerami A, et al. 1989.Cachectin/TNF or IL-1 α induces cachexia with redistributionof body proteins. Am J Physiol 256: R659-R665.
55. Fransen L, Muller R, Marmenout A, Tavernier J, Van der HeydenJ, Kawashima E, Chollet A, Tizard R, Van Heuverswyn H, Van Vliet A, et al. 1985. Molecular cloning of mouse tumour necrosisfactor cDNA and its eukaryotic expression. Nucleic AcidsRes 13: 4417-4429.
56. Gallagher IJ, Stephens NA, MacDonald AJ, Skipworth RJ, Husi H, Greig CA, Ross JA, Timmons JA, Fearon KC. 2012. Suppressionof skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies.Clin Cancer Res 18: 2817-2827.
57. Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. 2015. Anamorelin for patients with cancer cachexia:an integrated analysis of two phase 2, randomised, placebocontrolled,double-blind trials. Lancet Oncol 16: 108-116.
58. Goldberg AL, Goodman HM. 1969. Relationship between cortisoneand muscle work in determining muscle size. J Physiol200: 667-675.
59. Greenstein JP. 1947. Biochemistry of Cancer. Academic Press,Inc., New York.Grossberg AJ, Scarlett JM, Zhu X, Bowe DD, Batra AK, Braun TP
60. Grossberg AJ, Scarlett JM, Zhu X, Bowe DD, Batra AK, Braun TP, Marks DL. 2009. Arcuate nucleus proopiomelanocortin neuronsmediate the acute anorectic actions of leukemia inhibitoryfactor via gp130. Endocrinology 151: 606-616.
61. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr.2000. NF-κB-induced loss of MyoD messenger RNA: possiblerole in muscle decay and cachexia. Science 289: 2363-2366.
62. Han HQ, Zhou X, Mitch WE, Goldberg AL. 2013. Myostatin/activinpathway antagonism: molecular basis and therapeutic potential.Int J Biochem Cell Biol 45: 2333-2347.
63. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the nextgeneration. Cell 144: 646-674.
64. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, Wang J, Bloomston M, Muscarella P, Nau P, et al.2013. NF-κB-mediated Pax7 dysregulation in the muscle microenvironmentpromotes cancer cachexia. J Clin Invest123: 4821-4835.
65. HeWA, Calore F, Londhe P, Canella A, Guttridge DC, Croce CM.2014. Microvesicles containing miRNAs promote muscle celldeath in cancer cachexia via TLR7. Proc Natl Acad Sci 111:4525-4529.
66. Holroyde CP, Skutches CL, Boden G, Reichard GA. 1984. Glucosemetabolism in cachectic patients with colorectal cancer.Cancer Res 44: 5910-5913.
67. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, et al. 2014. MABp1,a first-in-class true human antibody targeting interleukin-1αin refractory cancers: an open-label, phase 1 dose-escalationand expansion study. Lancet Oncol 15: 656-666.
68. Jasani B, Donaldson LJ, Ratcliffe JG, Sokhi GS. 1978. Mechanismof impaired glucose tolerance in patients with neoplasia. Br JCancer 38: 287-292.
69. Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P,Weston R, Jayatilleke KM, Schloegel J, Talbo G, et al. 2015.Targeting of Fn14 prevents cancer-induced cachexia and prolongssurvival. Cell 162: 1365-1378.
70. Jones A, Friedrich K, Rohm M, Schafer M, Algire C, Kulozik P,Seibert O, Muller-Decker K, Sijmonsma T, Strzoda D, et al.2013. TSC22D4 is a molecular output of hepatic wasting metabolism.EMBO Mol Med 5: 294-308.
71. Kawakami M, Cerami A. 1981. Studies of endotoxin-induceddecrease in lipoprotein lipase activity. J Exp Med 154:631-639.
72. Khal J, Hine AV, Fearon KC, Dejong CH, Tisdale MJ. 2005. Increasedexpression of proteasome subunits in skeletal muscleof cancer patients with weight loss. Int J Biochem Cell Biol 37:2196-2206.
73. Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, Spiegelman BM. 2014. Tumour-derived PTH-related protein triggersadipose tissue browning and cancer cachexia. Nature 513:100-104.
74. Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, Hodin RA, Spiegelman BM. 2015. PTH/PTHrP receptor mediatescachexia in models of kidney failure and cancer. CellMetab doi: 10.1016/j.cmet.2015.11.003.
75. Klein GL, Petschow BW, Shaw AL, Weaver E. 2013. Gut barrierdysfunction and microbial translocation in cancer cachexia:a new therapeutic target. Curr Opin Support Palliat Care 7:361-367.
76. Kwon Y, Song W, Droujinine IA, Hu Y, Asara JM, Perrimon N.2015. Systemic organwasting induced by localized expressionof the secreted insulin/IGF antagonist ImpL2. Dev Cell 33:36-46.
77. Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN,Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F, et al. 2014. An antibody blocking activin type II receptors inducesstrong skeletal muscle hypertrophy and protects fromatrophy. Mol Cell Biol 34: 606-618.
78. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. 2008. Cachexia: common, deadly, with an urgent need forprecise definition and new therapies. Am J Cardiol 101:8E-10E.
79. Le Bricon T, Gugins S, Cynober L, Baracos VE. 1995. Negative impactof cancer chemotherapy on protein metabolism inhealthy and tumor-bearing rats. Metabolism 44: 1340-1348.
80. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. 2004. Multiple types ofskeletal muscle atrophy involve a common programof changesin gene expression. FASEB J 18: 39-51.
81. Lee SJ, McPherron AC. 2001. Regulation of myostatin activityand muscle growth. Proc Natl Acad Sci 98: 9306-9311.
82. Li G, Klein RL, Matheny M, King MA, Meyer EM, Scarpace PJ.2002. Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervationof brown adipose tissue and underlies one mechanism ofbody weight reduction in rats. Neuroscience 115: 879-889.
83. Lin JZ, Martagon AJ, Cimini SL, Gonzalez DD, TinkeyDW, Biter A, Baxter JD, Webb P, Gustafsson JA, Hartig SM, et al. 2015.pharmacological activation of thyroid hormone receptors elicitsa functional conversion of white to brown fat. Cell Rep 13:1528-1537.
84. Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD. 2014. Leucinesupplementation differentially enhances pancreatic cancergrowth in lean and overweight mice. Cancer Metab 2: 6.
85. Lok C. 2015. Cachexia: the last illness. Nature 528: 182-183.
86. Lokireddy S, Wijesoma IW, Teng S, Bonala S, Gluckman PD, McFarlane C, Sharma M, Kambadur R. 2012. The ubiquitin ligaseMul1 induces mitophagy in skeletal muscle in responseto muscle-wasting stimuli. Cell Metab 16: 613-624.
87. Ma JD, Heavey SF, Revta C, Roeland EJ. 2014. Novel investigationalbiologics for the treatment of cancer cachexia. ExpertOpin Biol Ther 14: 1113-1120.
88. Marin OS, Denny-Brown D. 1962. Changes in skeletal muscle associatedwith cachexia. Am J Pathol 41: 23-39.
89. Martignoni ME, Dimitriu C, Bachmann J, Krakowski-Rosen H, Ketterer K, Kinscherf R, Friess H. 2009. Liver macrophagescontribute to pancreatic cancer-related cachexia. Oncol Rep21: 363-369.
90. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD,Theurich S, Hausen AC, Schmitz J, Bronneke HS, et al.2014. Signaling by IL-6 promotes alternative activation ofmacrophages to limit endotoxemia and obesity-associated resistanceto insulin. Nat Immunol 15: 423-430.
91. Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, Bailey JL, Goldberg AL. 1994. Metabolic acidosis stimulatesmuscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes.J Clin Invest 93: 2127-2133.
92. Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, LeeMK, Lawlor KE, Wentworth JM, Vasanthakumar A, Gerlic M, Whitehead LW, et al. 2016. IL-18 production from theNLRP1 inflammasome prevents obesity and metabolic syndrome.Cell Metab 23: 155-164.
93. Nedergaard J, Cannon B. 2014. The browning of white adipose tissue:some burning issues. Cell Metab 20: 396-407.
94. Nedergaard J, Bengtsson T, Cannon B. 2007. Unexpected evidencefor active brown adipose tissue in adult humans. Am JPhysiol Endocrinol Metab 293: E444-E452.
95. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan L, Brombacher F, Locksley RM, Chawla A. 2011. Alternativelyactivated macrophages produce catecholamines tosustain adaptive thermogenesis. Nature 480: 104-108.
96. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. 1987. Tumors secreting humanTNF/cachectin induce cachexia in mice. Cell 50: 555-563.
97. Paspaliaris V, Langan B, DeAndrea R,Wood J, Tsouvelekas A, Demosthenes B. 2011. Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in the management of cancerrelatedcachexia. J Cachexia Sarcopenia Muscle 2: 209-261.
98. Patsouris D, Qi P, Abdullahi A, Stanojcic M, Chen P, Parousis A, Amini-Nik S, Jeschke MG. 2015. Burn induces browning ofthe subcutaneous white adipose tissue in mice and humans.Cell Rep 13: 1538-1544.
99. Penna F, Minero VG, Costamagna D, Bonelli G, Baccino FM, Costelli P. 2010. Anti-cytokine strategies for the treatmentof cancer-related anorexia and cachexia. Expert Opin BiolTher 10: 1241-1250.
100. Pennica D, Hayflick JS, Bringman TS, Palladino MA, GoeddelDV.1985. Cloning and expression in Escherichia coli of the cDNAfor murine tumor necrosis factor. Proc Natl Acad Sci 82:6060-6064.
101. Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, TsoliM, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G, et al. 2014. A switch from white to brown fat increases energyexpenditure in cancer-associated cachexia. Cell Metab20: 433-447.
102. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS, Mitch WE. 1996. Muscle wasting in insulinopenicrats results from activation of the ATP-dependent, ubiquitinproteasomeproteolytic pathway by a mechanism includinggene transcription. J Clin Invest 98: 1703-1708.
103. Raber J, O'Shea RD, Bloom FE, Campbell IL. 1997. Modulation ofhypothalamic-pituitary-adrenal function by transgenic expressionof interleukin-6 in the CNS of mice. J Neurosci 17:9473-9480.
104. Rohdenburg GL, Bernhard A, Krehbiel O. 1919. Sugar tolerance incancer. J Am Med Assoc 72: 1528-1530.
105. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. 2001. Mediation of IGF-1-inducedskeletal myotube hypertrophy by PI(3)K/Akt/mTORand PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3: 1009-1013.
106. Rosenthal CJ, Franklin EC. 1975. Variation with age and diseaseof an amyloid A protein-related serum component. J Clin Invest55: 746-753.
107. Rouzer CA, Cerami A. 1980. Hypertriglyceridemia associatedwith Trypanosoma brucei brucei infection in rabbits: role ofdefective triglyceride removal. Mol Biochem Parasitol 2:31-38.
108. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. 2002.Tumor necrosis factor-α suppresses adipocyte-specific genesand activates expression of preadipocyte genes in 3T3-L1 adipocytes:nuclear factor-κB activation by TNF-α is obligatory.Diabetes 51: 1319-1336.
109. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, Irving BA, et al. 2012. A PGC-1αisoform induced by resistance training regulates skeletal musclehypertrophy. Cell 151: 1319-1331.
110. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. 2004. Foxotranscription factors induce the atrophy-related ubiquitin ligaseatrogin-1 and cause skeletal muscle atrophy. Cell 117:399-412.
111. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM. 2006. PGC-1α protects skeletalmuscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci 103:16260-16265.
112. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M. 2009. Smad2 and 3 transcription factors controlmuscle mass in adulthood. Am J Physiol Cell Physiol 296:C1248-C1257.
113. Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, Stantzou A, Mouisel E, Toniolo L, Ferry A, et al. 2013. BMPsignaling controls muscle mass. Nat Genet 45: 1309-1318.
114. Schaefer M, Oeing CU, Rohm M, Baysal-Temel E, Lehmann LH, Bauer R, Volz HC, Boutros M, Sohn D, Sticht C, et al. 2016.Ataxin-10 is part of a cachexokine cocktail triggering cardiacmetabolic dysfunction in cancer cachexia. Mol Metab doi:10.1016/j.molmet.2015.11.004.
115. Schieber AM, Lee YM, Chang MW, Leblanc M, Collins B, Downes M, Evans RM, Ayres JS. 2015. Disease tolerance mediatedby microbiome E. coli involves inflammasome andIGF-1 signaling. Science 350: 558-563.
116. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. 2004. Myostatin mutation associatedwith gross muscle hypertrophy in a child. N Engl J Med350: 2682-2688.
117. Shum AM, Polly P. 2012. Cancer cachexia: molecular targets andpathways for diagnosis and drug intervention. Endocr MetabImmune Disord Drug Targets 12: 247-259.
118. Sidossis LS, Porter C, Saraf MK, Borsheim E, Radhakrishnan RS,Chao T, Ali A, Chondronikola M, Mlcak R, Finnerty CC, et al. 2015. Browning of subcutaneous white adipose tissuein humans after severe adrenergic stress. Cell Metab 22:219-227.
119. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A. 1988. Tumornecrosis factor not detectable in patients with clinical cancercachexia. J Natl Cancer Inst 80: 595-598.
120. Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH,Marstrand T, Ross JA, Guttridge DC, Lundell L, Fearon KC, et al. 2010. Using transcriptomics to identify and validate novelbiomarkers of human skeletal muscle cancer cachexia. GenomeMed 2: 1.
121. Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. 2011. Intramyocellular lipid droplets increasewith progression of cachexia in cancer patients. J CachexiaSarcopenia Muscle 2: 111-117.
122. Strassmann G, Fong M, Kenney JS, Jacob CO. 1992. Evidence forthe involvement of interleukin 6 in experimental cancer cachexia.J Clin Invest 89: 1681-1684.
123. Suarez-Zamorano N, Fabbiano S, Chevalier C, Stojanovic O,Colin DJ, Stevanovic A, Veyrat-Durebex C, Tarallo V, Rigo D, Germain S, et al. 2015. Microbiota depletion promotesbrowning of white adipose tissue and reduces obesity. NatMed 21: 1497-1501.
124. Svaninger G, Gelin J, Lundholm K. 1987. Tumor-host wastingnot explained by adrenal hyperfunction in tumor-bearing animals.J Natl Cancer Inst 79: 1135-1141.
125. Teli MR, James OF, Burt AD, Bennett MK, Day CP. 1995. Thenatural history of nonalcoholic fatty liver: a follow-up study.Hepatology 22: 1714-1719.
126. Temparis S, Asensi M, Taillandier D, Aurousseau E, Larbaud D, Obled A, Bechet D, Ferrara M, Estrela JM, Attaix D. 1994. IncreasedATP-ubiquitin-dependent proteolysis in skeletal musclesof tumor-bearing rats. Cancer Res 54: 5568-5573.
127. Tisdale MJ. 2010. Are tumoral factors responsible for host tissuewasting in cancer cachexia? Future Oncol 6: 503-513.
128. Tomas FM, Munro HN, Young VR. 1979. Effect of glucocorticoidadministration on the rate of muscle protein breakdown invivo in rats, as measured by urinary excretion of N τ-methylhistidine.Biochem J 178: 139-146.
129. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. 2009. Myostatin reduces Akt/TORC1/p70S6K signaling,inhibiting myoblast differentiation and myotubesize. Am J Physiol Cell Physiol 296: C1258-C1270.
130. Tsoli M, Robertson G. 2012. Cancer cachexia: malignant inflammation,tumorkines, and metabolic mayhem. Trends EndocrinolMetab 24: 174-183.
131. Tsoli M, Swarbrick MM, Robertson GR. 2015. Lipolytic and thermogenicdepletion of adipose tissue in cancer cachexia. SeminCell Dev Biol doi: 10.1016/j.semcdb.2015.10.039.
132. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM,Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. 2009. Cold-activated brown adipose tissue in healthy men.N Engl J Med 360: 1500-1508.
133. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R,Niemi T, Taittonen M, Laine J, Savisto NJ, Enerback S, et al.2009. Functional brown adipose tissue in healthy adults. NEngl J Med 360: 1518-1525.
134. Wagner EF, Petruzzelli M. 2015. Cancer metabolism: a waste ofinsulin interference. Nature 521: 430-431.
135. Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC,John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, et al. 2015. Excess TGF-β mediates muscleweakness associatedwith bone metastases in mice. Nat Med 21: 1262-1271.
136. Weinberg RA. 2014. Coming full circle-from endless complexityto simplicity and back again. Cell 157: 267-271.
137. White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW, Carson JA.2011. Muscle oxidative capacity during IL-6-dependent cancercachexia. Am J Physiol Regul Integr Comp Physiol 300:R201-R211.
138. Williams A, Sun X, Fischer JE, Hasselgren PO. 1999. The expressionof genes in the ubiquitin-proteasome proteolytic pathwayis increased in skeletal muscle from patients with cancer. Surgery126: 744-749.
139. Willis RA. 1948. Pathology of Tumors. C.V. Mosby Co., St. Louis,MO.
140. Wing SS, Goldberg AL. 1993. Glucocorticoids activate the ATPubiquitin-dependent proteolytic system in skeletal muscleduring fasting. Am J Physiol 264: E668-E676.
141. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. 2001. Reversalof cancer anorexia by blockade of central melanocortin receptorsin rats. Endocrinology 142: 3292-3301.
142. Yeoh BS, Vijay-Kumar M. 2015. Debugging the host browns thefat. Nat Med 21: 1390-1391.
143. Yoneshiro T, Aita S, Matsushita M, Kayahara T, Kameya T, Kawai Y, Iwanaga T, Saito M. 2013. Recruited brown adiposetissue as an antiobesity agent in humans. J Clin Invest 123:3404-3408.
144. Yoshikawa T, Noguchi Y, Doi C, Makino T, Okamoto T, Matsumoto A. 1999. Insulin resistancewas connected with the alterationsof substrate utilization in patients with cancer. CancerLett 141: 93-98.
145. Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K. 2001. Insulinresistance in patients with cancer: relationships with tumorsite, tumor stage, body-weight loss, acute-phase response,and energy expenditure. Nutrition 17: 590-593.
146. Young SG, Zechner R. 2013. Biochemistry and pathophysiologyof intravascular and intracellular lipolysis. Genes Dev 27:459-484.
147. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. 2007. FoxO3 coordinately activatesprotein degradation by the autophagic/lysosomal and proteasomalpathways in atrophying muscle cells. Cell Metab 6:472-483.
148. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, et al. 2010. Reversal of cancercachexia and muscle wasting by ActRIIB antagonism leads toprolonged survival. Cell 142: 531-543.
149. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF,Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ.2002. Induction of cachexia in mice by systemically administeredmyostatin. Science 296: 1486-1488.